Baseline characteristics of patients enrolled in the study
| Characteristics | TNFi (n=470) | ADA only (n=196) | ETN only (n=274) |
| Sex (F), n (%) | 363 (77.2) | 151 (77.0) | 212 (77.4) |
| Age at baseline (years), mean (SD), n | 56.7 (11.9), 469 | 56.5 (11.9), 195 | 56.9 (12), 274 |
| BMI, median (IQR), n | 27.6 (23.7–32.5), 396 | 27.5 (23.5–32.6), 164 | 27.7 (23.9–23.3), 232 |
| Concurrent csDMARDs, n (%) | 393 (83.8) | 172 (88.2) | 221 (80.7) |
| Baseline DAS28, mean (SD), n | 5.8 (0.9), 434 | 5.7 (0.9), 178 | 5.8 (0.9), 256 |
| Tender joint count, median (IQR) | 15 (10–21) | 15 (11–21) | 14 (10–21) |
| Swollen joint count, median (IQR) | 8 (5-12) | 8 (2–12.5) | 9 (5-12) |
| CRP (mg/L), median (IQR) | 9.2 (3.7–25.8) | 8.3 (2.8–25.7) | 9.6 (4.2–26.7) |
| HAQ, mean (SD), n | 1.7 (0.6), 416 | 1.7 (0.6), 175 | 1.6 (0.6), 241 |
ADA, adalimumab; CRP, C reactive protein; csDMARDs, conventional synthetic disease-modifying anti-rheumatic drugs; DAS28, disease activity score in 28-joints calculated using 4-components; ETN, etanercept; F, female; HAQ, Health Assessment Questionnaire; IQR, interquartile range; SJC, swollen joint count; TJC, tender joint count; TNFi, tumour necrosis factor inhibitor.